The Cognitive Function and Ageing Studies

https://www.neurodegenerationresearch.eu/survey/the-cognitive-function-and-ageing-studies/

Title of the cohort

The Cognitive Function and Ageing Studies

Acronym for cohort

CFAS

Name of Principal Investigator

Title	Prof
First name	Carol
Last name	Brayne

Address of institution where award is held

Institution	Institute of Public Health, University of Cambridge
Street Address	Robinson Way
City	Cambridge
Postcode	CB2 0SR

Country

- United Kingdom

Website

http://www.cfas.ac.uk

Contact email

1. The cohort includes, or expects to include, incidence of the following conditions

- Alzheimer’s disease and other dementias
- Parkinson’s disease
- Neurodegenerative disease in general

When studies on the above condition(s) are expected to become possible

- Already possible

2a. Stated aim of the cohort

To find out how common dementia and associated conditions are in England and Wales and also, how many new cases of dementia develop each year

2b. Features distinguishing this cohort from other population cohorts

3a. i) Number of publications that involve use of cohort to date

190

3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)
3b. Publication list/link to where data or publications are accessible (if available)

http://www.cfas.ac.uk/pages/publications/searchpub.asp

3c. Information (i.e. research findings) expected to be gained from the population cohort
4a. Study criteria: age range of participants at recruitment

Age in years from: 65

To ('until death' if applicable): No limit

4b. Study criteria: inclusion criteria

The CFAS are population based studies of individuals aged 65 years and over living the community, including institutions. The fieldwork for this study began in 1991.

4c. Study criteria: exclusion criteria

N/A

5. Size of the cohort (i.e. number of participants enrolled)

- 10,001 – 15,000 participants

6a. Measures used to characterise participants
6b. Additional measures for participants with a clinical disorder
6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)

- No

7. Study design

- Prospective cohort
- Longitudinal
- Other (please specify)
- The follow-up has been determined by funding and the design of associated bolt-on studies.

8. Cases matched by

- Other health assessment (specify) / N/A

9a. Does the study include a specialised subset of control participants

- No

9b. If yes, description of specialised subset of control participants
10a. i) Data collection start date

01-01-1989

10a. ii) Data collection end date
10a iii) Data collection for this study is

- Data analysis ongoing

10b. Plans to continue the cohort study beyond the current projected end date

- Yes – funding applied for

11. Data collected

- Only through the study

12. System in place to enable re-contact with patients for future studies

- Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

13a. Format and availability of data stored in a database

	Yes/No	% available
Data summarised in database		
Database is web-based		
Database on spreadsheet	Yes STATA	
Database is on paper		
Other (specify)		

Language used:

English

13b. Format and availability of data held as individual records

	Yes/No	% available
Data held as individual records		
Data is web-based		
Data held on computer based records	Yes	
Data held on cards		
Other (specify)		

Language used:

English

14a. Are data available to other groups

Yes

14b. Access policy/mechanisms for access if data are available to other groups

- Apply to PI or co-ordinator at resource
- Access Committee mechanism

15. Data sharing policy specified as a condition of use

- Data made publicly available after a specified time point

16a. Are tissues/samples/DNA available to other groups

Yes

16b. i) Description of available tissues/samples/DNA

- Post-mortem donors: brain
- Living donors:blood

16b. ii) Form available tissues/samples/DNA are supplied in

- Primary Samples: Stabilised samples (frozen or fixed)

16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data

Yes

17. Is information on biological characteristics available to other groups

- No